VivoSeq
Other

Hepatotoxicity

6

Pipeline Programs↗

3

Active Trials↗

4

Companies Involved↗

Hepatotoxicity is an early-stage landscape with 6 programs across 4 companies. The most active players are Daiichi Sankyo, Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Kenvue Brands.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Daiichi Sankyo logo

Daiichi Sankyo

1 program

PreclinicalK

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

PreclinicalK

Kenvue Brands

1 program

PreclinicalB

Bukwang Pharmaceutical

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

7

clinical trials

Completed2 · 29%
Recruiting2 · 29%
Unknown status2 · 29%
Not yet recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1
Recruiting·UUniversity Hospital, Clermont-Ferrand·N/A·NCT06649474·100 enrolled
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
Recruiting·Daiichi Sankyo logoDaiichi Sankyo·N/A·NCT04635111·30 enrolled
Proof-of-concept to Evaluate the Efficacy and Safety of Prednisone in Idiosyncratic Hepatotoxicity
Not yet recruiting·FFundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud·Phase 2·NCT06251232·60 enrolled
The Efficacy of Silymarin on the Prevention of Hepatotoxicity From Antituberculosis Drugs
Completed·RRamathibodi Hospital·N/A·NCT01800487·80 enrolled
Acetaminophen-induced Hepatotoxicity in Chronic Alcohol Abusers
Completed·—·N/A·NCT00137059·40 enrolled
Hepatotoxicity Related to Protein Kinase Inhibitors
Unknown status·—·N/A·NCT05430126·600,000 enrolled
Effect of Prophylactic Use of Silymarin on Hepatotoxicity Induced by Anti-tuberculosis Drugs
Unknown status·SSeoul National University Hospital·N/A·NCT01436929·600 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)